Jonathan Leong, CEO; Simon Yi, President & COO, PhysioCue
Hypertension, a symptomless, silent killer, is considered as one of the leading causes of death and disability across the globe. According to the Centers for Disease Control and Prevention, about half of American adults are sufferers of hypertension, which costs about billions of dollars annually to treat it and other related complications. Things are not different at the global level. On the other hand, severe headaches and migraines that have a debilitating effect on humans have a similar epidemical statistic. What is the remedy for these life-threatening health conditions? Drugs? Invasive methods? Antihypertensive and anti-migraine drug markets are saturated with several invasive treatment methods and over-the-counter pain relievers. However, the question is whether they are efficient in alleviating the impacts of hypertension and migraine. Amid this uncertainty, their deadly side effects and high costs are also matters of concern, forcing people to look for alternative measures to get rid of hypertension and migraine. Enter PhysioCue.
Catering to this global need, this five-year-old consumer digital health and therapy device development company has developed a non-invasive hypertension therapy device and migraine/headache therapy device. “Proved to be efficient, safe, easy-to-use, and cost-effective, our innovative devices reduce the effects of hypertension and migraine without having any side effects associated with antihypertensive and headache drugs,” says Simon Yi, President and COO of PhysioCue.
PhysioCue’s handheld, portable hypertension therapy device helps in reducing patients’ blood pressure by using patented thermal neurostimulation technology. Applying it to the site of the carotid artery stimulates patients’ parasympathetic nervous system, which lowers the sympathetic drive and hence the blood pressure. Continuous use of this device results in conditioning the baroreceptors to regain proper balance in patients’ autonomic system, which helps in keeping blood pressure at normal levels.
PhysioCue conducted a proof-of-concept pilot clinical trial with 60 subjects for 68 days, in which it was proved that its hypertension therapy device is equivalent to antihypertensive drugs in lowering high blood pressure for stage one and two patients. This is what makes it one of the most sought-after solutions to reduce blood pressure by eliminating the need for drug intake or invasive measures. The device works effectively for patients of all ages, ethnicity, gender, and regardless of their blood pressure level or current medications.
Proved to be efficient, safe, easy-to-use, and cost-effective, our innovative devices reduce the effects of hypertension and migraine without having any side effects associated with antihypertensive and headache drugs
To allow patients and caretakers to track and monitor blood pressure variations, PhysioCue has introduced its next-generation homecare therapy device. It is a complete solution for treating and monitoring patients’ high blood pressure by maintaining the hypertension therapy device’s performance and employing innovative biosensor technology. It includes unique PPG and ECG biosensors that measure blood pressure from fingers, record and transmit data, via PhysioCue mobile app, to the cloud for dissemination to healthcare providers or family members.
PhysioCue develops a non-invasive, handheld migraine and headache therapy device that uses patented thermal neurostimulation, at a precise temperature and duration, to reduce migraine and headache. By placing the device against the temples for 5 minutes, it can decrease referred pain by modulating the release of inflammatory mediators. Continuous use of this device helps in reducing the number of migraine days per month, while the use of painkillers provides temporary relief. “To help people track their migraine attacks and manage them effectively, we are releasing Migraine Cue, a mobile application that allows users to keep a record of their pain and treatment, receive insightful reports, and exchange information with other patients,” says Jonathan Leong, CEO of PhysioCue.
With such advanced devices and state-of-the-art technologies, PhysioCue is on a mission to empower people affected by hypertension and migraine to take care of themselves and live healthy. In order to reach out to a greater population and cement its position in the market, the company is focused on strengthening its strategic regional partnerships and honing its go-to-market strategy. PhysioCue continues to enhance its expertise in new sensor technologies to increase the potential of its devices.